Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
GPCR
#1493
Structure Therapeutics Inc - American Depositary Shares
39.3
4
USD
-2.07%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-2.07%
Monthly Change
-4.79%
6 month change
+11.57%
Year Change
+47.12%
Previous Close
40.1
7
Open
39.3
4
Low
39.3
4
High
39.3
4
Volume
48
Markets
US Stock Market
Healthcare
GPCR
Open full chart
Full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2023
2024
2025
Current
Key stats
Total common shares outstanding
46.6 M
57.34 M
70.84 M
71.07 M
Valuation ratios
Enterprise value
1.75 B
1.39 B
4.13 B
2.45 B
Price to earnings ratio
-49.86
-34.77
-86.94
-44.26
Price to sales ratio
—
—
—
—
Price to cash flow ratio
55.99
36.72
-55.59
-43.28
Price to book ratio
9.83
4.95
8.15
1.62
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
-0.19
-0.14
-0.09
-0.05
Return on equity %
-0.2
-0.14
-0.09
-0.05
Return on invested capital %
-2 016.2
-2 707.26
-671.83
-456.41
Gross margin %
—
—
—
—
Operating margin %
—
—
—
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
19.14
24.74
24.81
26.16
Inventory turnover
—
—
—
—
Asset turnover
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
-0.72
-0.74
-1.25
-0.9
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
4.24
5.59
8.14
6.71
Net current asset value per share
4.3
5.64
8.84
6.86
Tangible book value per share
4.11
5.48
8.54
6.66
Working capital per share
4.07
5.42
8.49
6.6
Book value per share
4.11
5.48
8.54
6.66
News
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
NVO Rallies 21% in a Month: How Should Investors Play the Stock?
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market - TipRanks.com
LLY's Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes Study